New technologies and adaptations of existing technologies can improve platform processes.
Jay Wealand
Advertisement
Jay Wealand is a principal scientist at Pfizer BioTherapeutics Research and Development
Articles by Jay Wealand
Advertisement
Latest Updated Articles
Advances in Monoclonal Antibody PurificationPublished: March 2nd 2010 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
AI-Driven Organ-on-Chip Platforms Are Changing the Game in Bio/Pharma R&D
2
Q&A: An Evolution in Enzyme Engineering with Zymvol’s Marina Cañellas
3
Novartis–Avidity Biosciences Deal Highlights Next-Gen RNA Manufacturing Potential
4
Regulatory Challenges for Global Manufacturing of Vaccines
5
